Tauranga, New Zealand--By almost all parameters measured, the efficacy of holmium laser transurethral procedures in the prostate match or exceed that of similar open and transurethral procedures, according to a significant body of work by Peter J. Gilling, MD, urologic consultant at Tauranga Hospital, New Zealand. Dr. Gilling's research has centered on two procedures'holmium laser resection of the prostate (HoLRP) and holmium laser enucleation of the prostate (HoLEP)-although HoLRP has essentially been replaced by the 100-watt HoLEP (Lumenis, Santa Clara, CA).
Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.